New hope for giant cell arteritis patients?

NCT ID NCT04474847

Recruiting now Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug abatacept can help people with giant cell arteritis, a condition that causes inflammation in blood vessels. About 78 adults with newly diagnosed or relapsing disease will receive either abatacept or a placebo for up to 12 months. The goal is to see if abatacept can keep the disease under control without the need for long-term steroids.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

arteritis autoimmune disease Giant Cell Arteritis immune system disorder temporal arteritis vasculitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GIANT CELL ARTERITIS

Contacts and locations

Locations

Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States
Hospital for Special Surgery
RECRUITING

New York, New York, 10021, United States
Hôpital du Sacré-Coeur de Montréal Université de Montréal
RECRUITING

Montreal, Quebec, H4J 1C5, Canada
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States
Mount Sinai Hospital
RECRUITING

Toronto, Ontario, Canada
St. Joseph's Healthcare
RECRUITING

Hamilton, Ontario, Canada
University of British Columbia
RECRUITING

Vancouver, British Columbia, V6Z 2C7, Canada
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Vanderbilt University
RECRUITING

Nashville, Tennessee, 37240, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.